product name Nicardipine HCl
Description: Nicardipine HCl is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders. Nicardipine hydrochloride is the hydrochloride salt form of Nicardipine and a potent L-type calcium channel protein inhibitor. It is described to alter cytochrome P-450 3A expression through induction of CYP3A. Nicardipine blockade of Ca2+ channels has been correlated to antihypertensive effects.
References: Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2885-90; J Hypertens Suppl. 1996 Oct;14(3):S29-35.
515.99
Formula
C26H29N3O6.HCl
CAS No.
54527-84-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (193.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
RS-69216
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19403660
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Nicardipine (100 mg/kg) produces a significant transient decrease in retinal blood flow in cats. Nicardipine (100 mg/kg) produces a significant increase in ONH blood flow despite a significant decrease of the mean arterial blood pressure in cats, which suggests that nicardipine could have a beneficial effect on ONH tissue. Nicardipine significantly reduces systolic pressure in the spontaneously hypertensive rats (SHR). Nicardipine significantly reduces the thickness of the tunica media, the media: lumen ratio and increases the luminal area, primarily at the level of small pial arteries and of intracerebral arteries in the spontaneously hypertensive rats (SHR). Nicardipine increases the number of neurones in the frontal cortex and in the occipital cortex of SHR and counters hyperplasia and hypertrophy of GFAP-immunoreactive astrocytes. Nicardipine increases the number of neurones in the CA1 field of the hippocampus and decreases the number and the size of astrocytes of the white matter and grey matter, respectively. |
| Animal model | |
| Formulation & Dosage | |
| References | Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2885-90; J Hypertens Suppl. 1996 Oct;14(3):S29-35. |
Related Posts
product name Nicardipine HCl
Description: Nicardipine HCl is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders. Nicardipine hydrochloride is the hydrochloride salt form of Nicardipine and a potent L-type calcium channel protein inhibitor. It is described to alter cytochrome P-450 3A expression through induction of CYP3A. Nicardipine blockade of Ca2+ channels has been correlated to antihypertensive effects.
References: Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2885-90; J Hypertens Suppl. 1996 Oct;14(3):S29-35.
515.99
Formula
C26H29N3O6.HCl
CAS No.
54527-84-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (193.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
RS-69216
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19403660
| In Vitro |
In vitro activity: Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Nicardipine (100 mg/kg) produces a significant transient decrease in retinal blood flow in cats. Nicardipine (100 mg/kg) produces a significant increase in ONH blood flow despite a significant decrease of the mean arterial blood pressure in cats, which suggests that nicardipine could have a beneficial effect on ONH tissue. Nicardipine significantly reduces systolic pressure in the spontaneously hypertensive rats (SHR). Nicardipine significantly reduces the thickness of the tunica media, the media: lumen ratio and increases the luminal area, primarily at the level of small pial arteries and of intracerebral arteries in the spontaneously hypertensive rats (SHR). Nicardipine increases the number of neurones in the frontal cortex and in the occipital cortex of SHR and counters hyperplasia and hypertrophy of GFAP-immunoreactive astrocytes. Nicardipine increases the number of neurones in the CA1 field of the hippocampus and decreases the number and the size of astrocytes of the white matter and grey matter, respectively. |
| Animal model | |
| Formulation & Dosage | |
| References | Invest Ophthalmol Vis Sci. 1992 Sep;33(10):2885-90; J Hypertens Suppl. 1996 Oct;14(3):S29-35. |